Veeva Vault CRM vs Salesforce Life Sciences Cloud: 2026 Buyer's Guide

Summary

Pharma commercial CRM is in the middle of a once-in-a-generation reset. Veeva built its ~$2.5B commercial business on the Salesforce platform; in December 2022 Veeva announced it would migrate off Salesforce onto its own proprietary Vault architecture, and Salesforce responded by launching Life Sciences Cloud (later rebranded Agentforce Life Sciences) as a direct replacement — co-developed with IQVIA using licensed OCE technology (Source: IQVIA/Salesforce Partnership, April 2024, accessed 2026-04-19).

Where the two vendors stand as of April 2026:

Metric	Veeva Vault CRM	Salesforce Life Sciences Cloud
Live customers	125+ worldwide (March 2026)	70+ (early 2026)
Top-20 biopharma committed	10 of top 20	2 of top 20
Marquee wins	BMS, Roche, Merck, GSK, Bayer, Novo Nordisk (intl ops), Boehringer Ingelheim, BioNTech, Pfizer Japan, AstraZeneca Japan	Novartis, AstraZeneca (global), Pfizer, Takeda, Boehringer Ingelheim (patient), Fresenius Kabi, Fidia, Penumbra
Global CRM market share (2024)	~26.8% (Veeva)	~16.4% (Salesforce)
Pharma CRM share	~80% of life sciences CRM seats	Growing from small base
Hard sunset	Legacy Salesforce-hosted Veeva CRM: Dec 31, 2029	N/A — Salesforce is the receiving platform

(Sources: Veeva 125+ live press release, March 2026; Salesforce 70+ customers announcement, 2025; IntuitionLabs 2026 CRM Guide, accessed 2026-04-19.)

The core buyer question in 2026 is not “which is better” — it is “do I re-platform onto Vault, or do I take this forced migration as the moment to leave Veeva entirely?” The answer depends on where else the organization invests in Salesforce vs. Veeva modules, appetite for multi-year re-implementation, and strategic posture on AI/agentic automation.

---

Why This Comparison Matters Now

The deadline is real, and it was just pulled in. Veeva originally targeted September 2030 end-of-support for its Salesforce-hosted legacy CRM. In early 2026 Veeva accelerated that cutoff to December 31, 2029 — roughly nine months earlier (Source: Veeva March 2026 announcement, accessed 2026-04-19). The stated reason is strong Vault CRM migration momentum; the practical effect is a smaller window for customers who have not yet committed.

The migration is a re-implementation, not a data transfer. The Salesforce architecture most pharmas invested in — custom objects, Apex triggers, Force.com integrations, MyInsights dashboards — does not port automatically to Vault. Vault CRM has its own data model, its own UI framework (VMOCs instead of Visualforce), and its own integration layer. Moving is effectively a greenfield CRM project (Source: Craftware migration analysis; Grax Veeva-Salesforce migration guide, accessed 2026-04-19).

Backwards math on the deadline. If a typical enterprise pharma CRM migration runs 18–36 months with strong sponsorship (Source: IntuitionLabs migration roadmap, accessed 2026-04-19), any organization that has not started by mid-2027 is at risk of running past the Dec 2029 cutoff — or compressing validation to dangerous timelines for a GxP-adjacent system.

Buyer action items by timeline:

By when	What the buyer must do
Q2 2026	Complete vendor RFP and platform decision (Vault vs. LSC)
Q3–Q4 2026	Sign SOW with SI partner; begin design and data mapping
2027	Build, configure, pilot with 1–2 business units or countries
2028	Parallel-run phase — legacy and new CRM in production simultaneously
Q1–Q3 2029	Global rollout waves, region by region
Dec 31, 2029	Hard end-of-support on legacy Veeva CRM on Salesforce

Pharmas that delay into 2027 will almost certainly need to negotiate extended-support fees from Veeva or accept unsupported operation — neither is acceptable for a commercial system that feeds Sunshine Act reporting and validated call records.

---

Head-to-Head Capability Matrix

Ratings: L = Leader / most mature, P = Parity / credible, G = Gap / still maturing. Based on public product roadmaps and analyst coverage as of April 2026.

Capability	Veeva Vault CRM	Salesforce Life Sciences Cloud
Multichannel CRM (field + inside sales)	L	P
eDetailing / Approved Email / CLM	L (native PromoMats integration)	G (roadmap; partner-dependent)
Medical Affairs / KOL engagement	L (CRM for Medical, MedComms)	G (medical ops intelligence on Oct 2026 roadmap)
MedComms / MSL workflows	L (Vault MedComms)	G
Field Coaching	P (coaching reports)	P (coaching templates Oct 2026 roadmap)
Territory & Call Planning	L	P (native to Sales Cloud)
Sample Management / Sunshine Act	L (validated, purpose-built)	G (still building parity)
Events Management (compliant HCP events)	L (Vault Events)	G (Oct 2026 target GA)
AI / Agentic automation	P (Veeva AI Agents GA Dec 2025 — Pre-call, Voice, Content, Free Text)	L (Agentforce platform, Einstein, $4B+ R&D)
Content Management (promotional)	L (PromoMats — industry standard)	G (no Vault equivalent)
Regulatory Submissions (RIM)	L (Vault RIM)	Not offered
Quality / LIMS / Safety (validated GxP)	L (Vault QualityOne, LIMS, Safety)	Not offered
Patient Services / Hub workflows	P (via partner ecosystem)	L (Patient Services module, Health Cloud lineage)
Marketing Cloud / omnichannel orchestration	G	L (native Marketing Cloud + Data Cloud)
Data Cloud / unified patient-HCP 360	P (Network + Compass + Crossix)	L (Salesforce Data Cloud is foundational)
Clinical Trials (recruitment, e-consent)	L (Vault Clinical Suite)	P (LSC includes trials modules)
Open ecosystem vs. single-vendor	Single-vendor closed stack	Open Salesforce AppExchange ecosystem
Validation-ready (GxP)	L (purpose-built)	P (requires IQ/OQ/PQ layering)
Time to value (new deployments)	Faster (pharma-specific templates)	Slower (customization + ISVs required)
Mobile / offline field rep app	L (Veeva CRM mobile with offline sync)	P (Salesforce Mobile + LWC Offline)

(Sources: IntuitionLabs 2026 CRM Guide; HIT Consultant, Oct 2025; Customertimes Veeva-Salesforce field guide; Veeva AI Agents launch, accessed 2026-04-19.)

The Capability Summary in One Sentence

Veeva wins on pharma-specific depth (regulatory, quality, medical affairs, validated workflows) and time-to-value; Salesforce wins on platform breadth (marketing, data, AI), ecosystem openness, and agentic automation maturity. Everything else is on a roadmap race.

---

Customer Base & Market Shares

Veeva Vault CRM Adoption

• 125+ customers worldwide live on Vault CRM as of March 3, 2026, spanning the U.S., Europe, and Japan (Source: Veeva press release, accessed 2026-04-19).
• 10 of the top 20 global biopharma committed, up from 4 in November 2024 and 7 in October 2025.
• Public top-20 commitments: Bristol Myers Squibb (Sept 2025), Roche (Nov 2025), Merck (Jul 2025), GSK, Bayer, Boehringer Ingelheim (Nov 2024), Novo Nordisk International Operations (Jan 2026), BioNTech, plus top-20 wins in Japan. (Sources: BMS commitment; Roche adoption; GSK & Bayer case study; BioNTech/BI/GSK blog, accessed 2026-04-19.)
• Market share in pharma CRM: ~80% of life sciences CRM seats globally, per Veeva and third-party analyst estimates.

Salesforce Life Sciences Cloud Adoption

• 70+ life sciences customers selected Life Sciences Cloud as of Sept 2025 announcements (Source: Salesforce 70+ announcement, accessed 2026-04-19).
• Flagship top-20 wins: Novartis (Dec 17, 2025 — 5-year global rollout of Agentforce 360 for Life Sciences); AstraZeneca (Dec 4, 2025 — unified global platform); Takeda (May 19, 2025 — global CRM platform); Pfizer (early adopter). (Sources: Novartis release; AstraZeneca release; Takeda release, accessed 2026-04-19.)
• Additional early adopters: Boehringer Ingelheim (Patient Excellence organization — not the full commercial org, which committed to Veeva), Fresenius Kabi, Fidia, Penumbra, Protas (Source: Salesforce Fidia/Pfizer availability post, accessed 2026-04-19).
• IQVIA OCE installed base: ~400 customers across 130+ countries; IQVIA will continue to market OCE through 2029 before facilitating transition to LSC (Source: IQVIA/Salesforce announcement, accessed 2026-04-19).

Neutral Tally of Top-20 Biopharma

Status	Veeva Vault CRM	Salesforce LSC / Agentforce
Publicly committed	BMS, Roche, Merck, GSK, Bayer, Boehringer Ingelheim, Novo Nordisk (intl), BioNTech + 2 Japan-market top-20s	Novartis, AstraZeneca, Takeda, Pfizer
Partial / regional	Pfizer Japan, AstraZeneca Japan	Boehringer Ingelheim (patient org only)
Undisclosed / in play	Remaining top-20 with no public commitment

The 10-vs-2 scorecard massively favors Veeva on committed top-20s — but Novartis and AstraZeneca represent the two largest publicly announced defections and validate Salesforce as a credible enterprise choice. More importantly, the IQVIA OCE book (~400 customers) is a captive pipeline that Salesforce and IQVIA will jointly convert through 2029.

---

Migration Considerations

Re-platforming a pharma CRM is not a lift-and-shift — it is a validated re-implementation with commercial, regulatory, and operational stakes.

Data Complexity

• Custom objects and Apex triggers on legacy Salesforce-hosted Veeva CRM must be re-architected in Vault’s native data model. Vault does not support Apex or Force.com integrations natively (Source: Craftware, accessed 2026-04-19).
• MyInsights dashboards (Visualforce-based) require redevelopment as Vault MyInsights using X-Pages.
• Historical call records and Sunshine Act data must be migrated with full provenance. GxP retention rules drive decisions on what to migrate vs. archive.
• Integration points — MDM (Veeva Network), content management (PromoMats), ERP, data warehouse — all need reconnection and retesting.

Validation Requirements

Pharma CRMs are typically GxP-adjacent, not full GxP, but are generally validated to support Sunshine Act reporting and commercial compliance SOPs. Validation scope typically includes:

• User requirements specification (URS)
• Functional specification (FS)
• Design specification (DS)
• IQ (installation qualification), OQ (operational qualification), PQ (performance qualification)
• Traceability matrix between URS and test cases
• SOP updates for user onboarding, role changes, data entry

Vault CRM is purpose-built as a validation-ready platform (pre-qualified for IQ/OQ in most configurations). Salesforce LSC requires more validation layering — Salesforce is a general-purpose platform and pharma customers must build or buy their own validation tooling (Source: IntuitionLabs migration roadmap, accessed 2026-04-19).

Typical Timeline

Phase	Duration	What happens
Vendor selection / RFP	3–6 months	Capability eval, references, commercial terms
Design & architecture	3–6 months	Data model, integration architecture, SOP mapping
Build & configuration	6–9 months	Sandbox build, integrations, MyInsights, custom reports
Pilot / UAT	3–4 months	Single country or BU, full user community
Parallel run	3–6 months	Both systems live; reconciliation
Phased rollout	6–12 months	Country-by-country or brand-by-brand
Decommission	1–3 months	Archive, support wind-down
Total	18–36 months

Most programs land 18–24 months with a dedicated PMO, experienced SI (Accenture, Deloitte, Cognizant, Customertimes, PwC, QPharma), and executive sponsorship. 36+ months is typical when scope creep is uncontrolled or M&A interrupts the project (Source: IntuitionLabs migration roadmap, accessed 2026-04-19).

Change Management

The change-management load is significant regardless of destination. Field reps have to relearn a new UI, new call-capture workflow, new offline sync pattern. Coaching teams need new report logic. Medical affairs has to re-map MSL workflows. Large enterprises typically budget 15–25% of the total program cost for change management alone.

Partner Ecosystem

Veeva: Veeva Certified Partner Network — Accenture, Deloitte, Cognizant, Infosys, Wipro, Capgemini, IQVIA Technologies (yes, IQVIA is certified on both platforms), QPharma, Customertimes, Klick Health. Smaller specialists include Indegene, Axtria, ZS Associates.

Salesforce LSC: Salesforce Life Sciences Partner Network launched May 2025; early SI partners include Accenture, Deloitte, Cognizant, Capgemini, IBM, and pharma-focused Salesforce consultancies (Torrent Consulting, Avenga, Customertimes).

Most large SIs are dual-credentialed. Mid-market biotechs should verify partner depth in their specific therapeutic area and geography.

---

TCO & Pricing

Public pricing is limited for both vendors; ranges below are synthesized from analyst reports, consultant blogs, and anonymized RFP data.

Veeva Vault CRM

• Per-user pricing (estimated): $120–$200 per user per month for Vault CRM core; $500–$1,500 per user per month when bundled with broader Vault suite (PromoMats, Events, Medical, Network) (Source: IntuitionLabs Veeva pricing guide, accessed 2026-04-19).
• Typical deployment size: 500–5,000 rep seats for mid/large pharma; sub-200 seats for emerging biotech.
• Implementation services: $10K–$50K for small biotech; $500K–$1M+ for large-scale global rollouts (Source: IntuitionLabs Veeva implementation costs, accessed 2026-04-19).
• Add-ons: Veeva AI Agents priced on usage-based model (per agent invocation); Compass and Crossix priced separately per country/module.
• Savings for existing Vault customers: Customers already using Vault PromoMats, Events, or Medical benefit from shared data model and platform licenses — typical integration savings of 20–30% vs. building the same capabilities on Salesforce.

Salesforce Life Sciences Cloud

• Per-user pricing: Salesforce does not publish LSC-specific pricing. Industry estimates suggest $150–$300 per user per month for LSC Customer Engagement depending on feature tier, with Enterprise/Unlimited Sales Cloud as the underlying license (~$165–$330/user/mo list).
• Data Cloud add-on: Priced per credit consumed; typical enterprise spend $500K–$5M+ annually depending on data volume.
• Agentforce AI: Consumption pricing (~$2 per agent conversation at list; enterprise deals negotiated).
• MuleSoft, Marketing Cloud, Service Cloud: Separate license sessions often required for full LSC value proposition; each $100K–$1M+ annual commitments.
• Implementation services: Typically 1.5–3x license cost over life of deployment, driven by customization and ISV integrations for pharma-specific workflows not yet native in LSC.

TCO Illustrative — 2,000-Rep Pharma, 5-Year TCO

Cost category	Vault CRM	Salesforce LSC
Platform licenses	$18–30M	$20–40M
Implementation services	$5–15M	$10–25M
Integrations	$2–5M	$4–8M
Data/AI add-ons	$3–8M	$5–15M (Data Cloud + Agentforce)
Validation & SOP	$1–3M	$2–5M (more validation layering)
Change management	$2–5M	$3–6M
Total 5-yr TCO (est.)	$31–66M	$44–99M

(Synthesized from IntuitionLabs, consultant blogs, and public pharma earnings transcripts; ranges reflect deal-size variability. All figures approximate.)

Salesforce LSC typically runs 20–40% higher TCO than Vault CRM for a comparably sized pharma — driven by Data Cloud consumption, Agentforce usage, MuleSoft integrations, and heavier validation/customization requirements. The offset: organizations that already run Salesforce Marketing Cloud, Service Cloud, or Sales Cloud in other business units amortize platform licenses across multiple use cases, which can flip the math. The single most important TCO variable is: does your organization already have significant Salesforce spend outside of commercial CRM?

---

Best-For Recommendations

Best for Veeva Vault CRM

• Mid-size and large pharma already on Vault outside of CRM — if you run Vault PromoMats, Vault Events, Vault Medical, or Vault RIM, staying on Veeva keeps a unified data model and single vendor relationship. Moving CRM off-platform means duplicate identity, content, and HCP master data across two vendors.
• Pharma with heavy regulatory/quality integration needs — Vault Safety (PV), Vault QualityOne, Vault RIM, and Vault CRM share a common platform. No Salesforce equivalent exists. If you run validated R&D and Quality on Vault, CRM-on-Vault is the default choice.
• Medical-affairs-intensive organizations — Vault CRM for Medical and Vault MedComms are industry-leading for MSL workflows. Salesforce has Medical Ops Intelligence on its October 2026 roadmap but has no track record here.
• Smaller/emerging biotechs valuing time-to-value — Veeva’s pharma-specific templates and validation-ready platform get a 100-rep field force operational in 4–6 months. Salesforce LSC typically requires 8–12 months plus customization.
• Compliance-conservative buyers — validated, purpose-built, well-understood by FDA auditors.

Best for Salesforce Life Sciences Cloud

• Enterprises with major existing Salesforce investment — if Marketing Cloud, Service Cloud, Data Cloud, or Sales Cloud already serve patient support, trade relations, or non-pharma business lines, LSC consolidates onto a single vendor and a unified Customer 360.
• AI-first, omnichannel organizations — Agentforce’s agentic AI is more mature than Veeva AI Agents as of April 2026, and Salesforce’s $4B+ annual R&D accelerates the gap. Novartis, AstraZeneca, and Takeda cited agentic automation as their deciding factor.
• Patient Services / hub-heavy organizations — Salesforce Health Cloud lineage and Patient Services module offer more out-of-the-box capability than Veeva for enrollment, benefits verification, and hub workflows. Combined with Data Cloud for patient-HCP unification, LSC is stronger on the patient side.
• Global multi-BU pharmas wanting open ecosystem — Salesforce AppExchange has 5,000+ ISVs; Veeva’s ecosystem is smaller and more curated. If customization velocity matters more than pharma-specific depth, Salesforce wins.
• IQVIA OCE incumbents — the migration path from OCE to LSC is the jointly promoted route; existing OCE data models, analytics, and HCP hierarchies carry forward more naturally than a forklift onto Vault.

When Neither Is the Right Answer

• Very small biotechs (under 50 reps, pre-commercial) — both platforms are overkill. Lighter-weight CRMs like Pitcher, Viseven, or even standard Salesforce Sales Cloud (un-LSC’d) may fit better for a pre-launch team.
• Animal health / consumer health — both vendors have offerings but the pharma-specific capabilities are overpriced for non-human-pharma use cases.
• Legacy Oracle Siebel pharma customers — the bigger question is migration target; Siebel pharma is declining but not yet a CRM-decision-moment for most holdouts.

---

RFP Checklist

Questions a buyer should ask both vendors in a commercial CRM RFP:

1. Validation deliverables: What IQ/OQ/PQ documentation do you provide out of the box? What is incremental customer responsibility?
2. Sunshine Act / transparency reporting: Native capability, or via partner? Last customer audit experience?
3. Sample management: Closed-loop serialization, expiration, state-level compliance — show me the workflow.
4. Offline mobile: Conflict resolution logic when a rep loses connectivity for 3 days and then syncs?
5. Content management integration: What does it take to get an approved PI update into a rep’s CLM deck across 5,000 reps globally?
6. AI agentic roadmap: Which agents are GA today? Which are roadmap? What is the pricing model (per invocation, per seat, flat)?
7. Data residency: GDPR / China / Japan data residency — what regions are supported natively vs. with partner infrastructure?
8. Integration API maturity: REST/GraphQL coverage of the data model, rate limits, and webhook support — show me the OpenAPI spec.
9. TCO at scale: Provide 5-year TCO for 500, 2,000, and 5,000-rep configurations including all required add-ons for a full-featured deployment.
10. Migration path from current state: If we are on legacy Veeva-on-Salesforce, describe the migration plan, SI partners you recommend, and your commercial commitment to the transition.
11. Customer references in our therapeutic area and geography: Three customer references we can call, not case studies.
12. Release cadence and customer impact: How often are major releases? Are they opt-in? Breaking changes policy?
13. Disaster recovery and uptime SLAs: Public track record, RPO/RTO commitments, incident communication.
14. Exit clause: If we decide to leave in 5 years, what data formats do we get, at what cost, over what timeline?
15. Agentic AI governance: How do we audit an AI-generated pre-call plan? What is logged, what is traceable, and who is liable for an off-label recommendation an agent generates?
16. Data partner overlap: As your platform expands (Veeva Nitro, Salesforce Data Cloud, embedded payer/formulary signals), does it overlap with our existing market-access data subscriptions (MMIT/Norstella, IQVIA Payer Master, etc.)? What is the migration / displacement path if we standardize on yours, and what is your commitment if we keep the incumbent data partner?

---

Open Questions

1. Does the 10-vs-2 top-20 scorecard hold? Veeva’s public committed list relies on self-disclosure; some commitments (e.g., Boehringer Ingelheim) are partial — BI committed its commercial org to Vault CRM but its Patient Excellence org to Salesforce LSC. How many “commitments” are organization-wide vs. single-BU?
2. Will Salesforce accelerate its top-20 win rate in 2026? Novartis and AstraZeneca were both long-standing Salesforce-platform customers via legacy Veeva CRM. They chose to stay on Salesforce rather than migrate to Vault. How many of the remaining undisclosed top-20 are quietly in the same boat?
3. What happens to the ~400 IQVIA OCE customers after 2029? Public plan is transition to LSC. But OCE is mid-market-heavy and many customers are Europe/ROW. Whether Salesforce can convert 300+ of them before the OCE sunset is the single biggest swing variable in market share.
4. Will Veeva miss the Dec 2029 deadline? Veeva accelerated it from Sept 2030 as a confidence signal. If migrations slip — especially among enterprise customers who have not yet started — Veeva may have to re-extend, which would crack the forcing function. This is a major risk to Veeva’s 2027–2029 revenue ramp assumption.
5. Agentic ROI claims: Both vendors cite rep productivity uplift from AI (Pre-call agents, Voice agents, coaching agents). Independent verification of ROI at scale is still thin. By Q4 2026 we should see first customer outcome data.
6. Regulatory backstop: Could FDA or EMA formally mandate that pharma commercial CRM meet GxP validation standards? Veeva would benefit massively; Salesforce would face structural compliance cost.
7. What does “Patient Services” convergence look like? Both vendors are encroaching on hub services territory. Whether CRM + Patient Services + Hub converges into one platform or remains best-of-breed has major implications for hub vendors like ConnectiveRx, EVERSANA, and CareMetx.

---

Analyst Notes

Why the December 2029 deadline is real, not negotiable

Three reasons this is not a typical vendor extension dance:

1. Veeva’s financial incentive to enforce it. Veeva Commercial Cloud subscription revenue is ~$1.38B guided for FY2027. Each customer who stays on legacy CRM past 2029 is a customer Veeva cannot fully migrate to higher-ARR Vault CRM + AI Agents + Compass + Crossix bundles. Accelerating the deadline forces migration budgets off other priorities into Veeva’s wallet.
2. Technical impossibility of extended support. The legacy CRM runs on Salesforce’s Force.com platform; the Salesforce/Veeva commercial agreement governing that hosting is finite. Veeva cannot unilaterally keep the lights on after the contract terminates.
3. Veeva’s reputational asset. Veeva has told the market (and shareholders) this is the plan. Softening the deadline cracks the forcing function and signals weakness. Veeva’s premium valuation (~$40B market cap at 12-13x revenue) depends on successful migration execution.

Caveat: Veeva could introduce a paid “extended support” tier for 2030 stragglers — priced punitively enough to force migration but cushioning the hardest enterprise cases. This is consistent with every prior enterprise-software sunset (SAP, Oracle, Microsoft). Base case: some form of extended-support surcharge for 6–18 months post-Dec 2029, material enough to discourage reliance.

What happens to customers who delay migration

Organizations that have not started by Q2 2027 face three escalating problems:

1. Capacity crunch at SIs. Accenture, Deloitte, Cognizant, and the pharma-specialist SIs are finite. Vault CRM-certified architects are being hired aggressively through 2027. Late starters pay peak-market rates and get second-tier teams.
2. Feature freeze on legacy CRM. Veeva has stated no new features on legacy CRM — all innovation (AI Agents, Compass integration, Crossix integration) is Vault-only. Late movers fall 2–3 product-cycles behind competitors who migrated early.
3. Compliance exposure. A CRM running on unsupported software creates auditable findings at Sunshine Act reviews, FDA inspections, and SOX IT controls. A post-2029 incident (data breach, compliance gap) on an unsupported platform is career-ending for the CIO responsible.

What happens to OCE customers from IQVIA

This is the single most underappreciated dynamic in the CRM transition. IQVIA signed a joint development and transition agreement with Salesforce in April 2024; OCE will be supported through 2029 with joint marketing motion toward Life Sciences Cloud thereafter (Source: IQVIA/Salesforce announcement, accessed 2026-04-19).

• OCE customer base: ~400 customers, 130+ countries, ~17% of global pharma CRM share.
• Skew: Heavier Europe and ROW than Veeva; mid-market more than top-20.
• Transition risk: OCE customers have two unattractive options in 2029: migrate to Salesforce LSC (tested path, IQVIA-supported) or evaluate Veeva Vault CRM (greenfield, Veeva-led). Most will migrate to LSC because the data models, analytics, and HCP hierarchies are more continuous.
• Upside for Salesforce: Even capturing 50% of OCE’s 400-customer book adds 200+ LSC customers on top of Veeva-defection wins. That would position Salesforce at 300–500+ LSC customers by 2030 — a genuinely scaled challenger.
• Everest Group analysis: IQVIA + Salesforce is “a match made in heaven” for the mid-market, where Veeva’s premium pricing and single-vendor stance are a harder sell (Source: Everest Group analysis, accessed 2026-04-19).

Risk to Veeva valuation if Vault CRM migrations slip

Veeva trades at a premium multiple (~12–13x FY2026 revenue of $3.2B) predicated on:

• Successful 2026–2029 mass migration of 1,000+ CRM customers from legacy to Vault — no material defections to Salesforce.
• Net revenue retention of 120%+ driven by customers adding AI Agents, Compass, Crossix on top of Vault CRM.
• Development Cloud (R&D/Quality) as 2030+ growth engine — reaching ~$1.66B in FY2027 subscription revenue, projected to become larger than Commercial Cloud.

Material slippage in Vault CRM migrations — say, if 100+ customers defect to LSC beyond current expectations, or 300+ customers miss the Dec 2029 cutoff — would:

1. Compress NRR from ~120% toward ~105–110% as legacy seats churn faster than new bundles expand.
2. Force Veeva to extend legacy support (cost) or lose customers entirely (revenue).
3. Re-price the stock toward 7–9x revenue (historical life-sciences software median) — a ~30–45% multiple compression on top of revenue headwinds.

The migration isn’t just an IT event — it’s the single variable that determines Veeva’s next five years as a ~$3B vs. ~$6B company.

Structural observation: closed stack vs. open stack is the real question

Strip away the feature-by-feature matrix and the decision is philosophical:

• Veeva’s pitch: Single vendor, purpose-built, validated, fast-to-value. Pharma is different from other verticals and deserves a vertical vendor. Closed stack is a feature, not a bug.
• Salesforce’s pitch: Horizontal platform with vertical overlay. AI, marketing, data, service all on one cloud. Pharma is a customer segment, not a religion. Open ecosystem wins in the long run.

Both philosophies have Fortune 100 pharma adherents in 2026. Neither is obviously wrong. The decision is upstream of the feature comparison — it is a strategic posture on how the organization wants to build its customer technology stack for the 2030s.

Editorial view: The top-20 defections to Salesforce (Novartis, AstraZeneca, Takeda) are not outliers — they are the leading edge of a broader thesis that pharma customer engagement benefits from horizontal platform tooling plus pharma-specific overlays, rather than a single vertical vendor. If Salesforce ships its 2026 roadmap (events, field coaching, medical ops intelligence) on schedule and with production quality, the 10-vs-2 top-20 scorecard could narrow materially by 2028. If Salesforce misses those dates — which it has on other verticals before — Veeva consolidates the win. The 18-month window to watch is Q4 2026 through Q1 2028.

---

Editorial Firewall Disclosure

This comparison is written by the Rx Almanac editorial team using publicly available sources. Neither Veeva Systems nor Salesforce has sponsored, reviewed, or approved this content. Material public claims are cited inline where they need immediate context. Feedback and correction requests via the contact page; fact-based corrections are applied on verification, promotional edits are not accepted.

---

Related Pages

Vendor Profiles

• Veeva Systems
• Salesforce Life Sciences Cloud
• IQVIA — strategic partner to Salesforce, post-litigation détente with Veeva

Concepts

• AI & Automation in Pharma Services
• Medical Affairs & KOL Engagement
• Field Reimbursement Managers (FRM)

Categories

• Commercial Technology
• Data & Analytics

Related Comparisons

• ConnectiveRx vs EVERSANA — a parallel closed-specialist-vs-open-platform dynamic in hub services

Related Wiki Vendors (Auto)

Auto-generated cross-references closing audit-surfaced link gaps. Vendors named in the prose above without inline links are listed here so the wiki graph is queryable.

• Indegene
• Klick Health
• ZS Associates